nVerses Capital’s Humacyte HUMA Stock Holding History

nVerses Capital’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,500	Closed	-$24.5K	–	393
2024 Q3	$24.5K	Sell	4,500 -1,400	-24%	-$9.23K	0.01%	775
2024 Q2	$28.3K	Buy	+5,900	New	+$30.7K	0.02%	706

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

nVerses Capital's HUMA Position: Q4 2024 in Review

nVerses Capital sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 4,500 shares — an estimated $24.5K sold.

nVerses Capital first reported a position in HUMA in Q2 2024 and held it in 2 quarters. The position peaked at $28.3K in Q2 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

nVerses Capital reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 4,500 Humacyte shares in Q4 2024, an estimated $24.5K.
nVerses Capital first reported a position in Humacyte in Q2 2024 and held it in 2 quarters.
nVerses Capital's Humacyte position peaked at $28.3K in Q2 2024.
162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.